Published on
May 31, 2025
ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer
Hormone receptor-positive (HR+) breast cancer (BC) is the most common subtype of all BC diagnoses, accounting for nearly 70% of all cases. Initial treatment for patients with HR+ BC typically includes CDK4/6 inhibitors, which have led to improved …
Source:
Pharmacy Times
-
Neutral
